Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia

NCT: NCT07060066 · RECRUITING

NCT IDNCT07060066
StatusRECRUITING
Start Date2025-10-23
Completion2030-06-01
SponsorThe University of Texas Health Science Center, Houston (OTHER)
First posted
Last updated

Brief Summary

The purpose of this study is to provide an effective repetitive transcranial magnetic stimulation (rTMS) treatment for depressive symptoms in patients with schizophrenia. Schizophrenia patients with depressive symptoms will be exposed to rTMS to improve their symptoms.

Frequently Asked Questions

What is Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia?

Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia is a clinical trial registered under NCT07060066. Current status: RECRUITING.

What is the status of NCT07060066?

The current status of NCT07060066 (Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia) is: RECRUITING.

When did Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia start?

Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia started on 2025-10-23.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑